Summary:
- PDS Biotech, a clinical-stage immunotherapy company, announced positive results from a Phase 2 clinical trial of its lead candidate, PDS0101, in combination with standard-of-care treatment for advanced human papillomavirus (HPV)-associated cancers.
- The trial demonstrated a 36-month overall survival rate of 84.4%, which is a significant improvement compared to historical survival rates for this patient population.
- The results suggest that the PDS0101 combination therapy has the potential to become a new standard of care for the treatment of advanced HPV-associated cancers, providing hope for patients with this challenging disease.